awmsg logo



emtricitabine (Emtriva®)


Reference No. 122

Publication date:
10/08/2007


Appraisal information

emtricitabine (Emtriva®) 200 mg capsule
emtricitabine (Emtriva®) 10 mg/ml oral solution


Company: Gilead Sciences Ltd
BNF category: Infections
NMG meeting date: 17/05/2007
AWMSG meeting date: 12/06/2007
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 0407
Ministerial ratification: 30/07/2007

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Emtricitabine (Emtriva®) is recommended for use within NHS Wales as an option for the treatment of Human Immunodeficiency Virus (HIV-1) infected adults in combination with other antiretroviral agents for use in treatment-naïve patients in line with current BHIVA guidelines. It should only be prescribed by HIV specialists. AWMSG has requested the manufacturers make a further submission relating to paediatric use.
Final Appraisal Recommendation (FAR)
Download